What is Charles River Laboratories's granted (in shares)?

Charles River Laboratories (CRL) reported granted (in shares) of $135.00 in Q4 2025.

What does granted (in shares) mean?

The aggregate volume of share-based awards granted under specific compensation plans during the period. This metric helps investors track the dilution impact of new equity grants on existing shareholders.

Charles River Laboratories CRL Granted (in shares)

Granted (in shares) at other companies

West Pharmaceutical ServicesWST

——

Other financials

Income statement

See full

Revenue$995.8M+1.2%

Gross profit$349.0M-3.5%

Operating income$119.9M+60.6%

Net income-$14.8M-158%

EPS (diluted)-$0.30-160%

Balance sheet

See full

Cash & equivalents$198.2M-14.5%

Total debt$3.1B+1.9%

Total equity$2.9B-7.9%

Total assets$7.7B+2.0%

Cash flow

See full

Operating cash flow$41.1M-76.1%

CapEx$55.9M-5.8%

Free cash flow-$14.8M-113%

Valuation

See full

Market cap$8.91B+10.3%

Enterprise value$11.79B+8.5%

P/S2.2×+0.2×

Profitability

See full

Gross margin84.7%—

Operating margin13%-2.4pp

Net margin-4.6%—

FCF margin9.7%-4.3pp

Returns & leverage

See full

Return on equity-6%—

Debt / equity1×+0.1×

Current ratio1.4×-0.1×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.

The official record: Charles River Laboratories’s 10-K, filed February 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's granted (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Charles River Laboratories's granted (in shares)?: Charles River Laboratories (CRL) reported granted (in shares) of $135.00 in Q4 2025.
What does granted (in shares) mean?: The aggregate volume of share-based awards granted under specific compensation plans during the period. This metric helps investors track the dilution impact of new equity grants on existing shareholders.